Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
NCT06031181 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 390
Last updated 2023-12-13
Summary
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1019. The goal of this clinical trial is to confirm the therapeutic effect of sublobar resection for AIS/MIA diagnosed by intraoperative frozen section.
Conditions
- Lung Adenocarcinoma
- Frozen Section
- Sublobar Resection
Interventions
- PROCEDURE
-
Sublobar Resection
Sublobar Resection includes segmentectomy and wedge resection
Sponsors & Collaborators
-
Fudan University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-31
- Primary Completion
- 2026-01-01
- Completion
- 2030-12-31
Countries
- China
Study Locations
More Related Trials
-
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
NCT05636267 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Chemotherapy of NSCLC With or Without Icotinib
NCT02430974 ·Status: UNKNOWN ·Phase: PHASE2
-
Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung Carcinoma
NCT05165355 ·Status: UNKNOWN ·Phase: PHASE2
-
Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients
NCT06561620 ·Status: RECRUITING ·Phase: PHASE4
-
Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer
NCT05055999 ·Status: COMPLETED
-
Adjuvant Chemotherapy With or Without Intercalated Icotinib
NCT03983811 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma
NCT05132985 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients
NCT01843647 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC
NCT03300115 ·Status: UNKNOWN ·Phase: PHASE2
-
Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation
NCT02283424 ·Status: UNKNOWN ·Phase: PHASE4
-
Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)
NCT01833572 ·Status: COMPLETED ·Phase: PHASE2
-
Real-world Treatment Patterns and Clinical Outcomes in EGFR-mutant Unresectable Locally Advanced NSCLC
NCT04304638 ·Status: UNKNOWN
-
To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy
NCT06192849 ·Status: RECRUITING ·Phase: PHASE2
-
Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation
NCT01996098 ·Status: TERMINATED ·Phase: PHASE3
-
Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC
NCT02194556 ·Status: UNKNOWN ·Phase: PHASE4
-
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
NCT02215356 ·Status: UNKNOWN ·Phase: PHASE2
-
Icotinib for Completed Resected IB NSCLC With EGFR Mutation
NCT02264210 ·Status: COMPLETED ·Phase: PHASE2
-
The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation
NCT02820116 ·Status: UNKNOWN ·Phase: PHASE2
-
Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation
NCT01929200 ·Status: UNKNOWN ·Phase: PHASE2
-
Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma
NCT02125240 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer
NCT03866980 ·Status: TERMINATED ·Phase: PHASE3
-
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
NCT06300424 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
NCT05104788 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Furmonertinib as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutant NSCLC
NCT05987826 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC
NCT05536505 ·Status: RECRUITING ·Phase: PHASE2